期刊
NATURE REVIEWS CLINICAL ONCOLOGY
卷 8, 期 2, 页码 85-96出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2010.189
关键词
-
类别
资金
- lymphoma SPORE [1P50CA136411-01A1]
- Clay Chiles Lymphoma Fund
- Jack L. Stotsky Memorial Fund
- Living Legend Fund
An improved understanding of the molecular biology of cancer cell growth and survival and the role of the microenvironment in supporting the survival of cancer cells, including lymphoma cells, has led to the identification of a number of potential therapeutic targets. Despite these advances, drug development for lymphoma remains slow, inefficient, and frequently unfocused. Future work should focus on identifying 'driver' molecular defects of oncogenic pathways that can be targeted therapeutically, discovering predictive biomarkers for treatment response, and prioritizing promising drugs to accelerate their approval. This Review summarizes the current development status of novel agents for lymphoma and discusses strategies to move the field forward.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据